Aurinia Pharmaceuticals, Inc. (AUPH)
15.73
-0.48
(-2.96%)
USD |
NASDAQ |
Nov 13, 16:00
15.72
0.00 (0.00%)
After-Hours: 19:59
Aurinia Pharmaceuticals Enterprise Value : 1.680B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.680B |
| November 12, 2026 | 1.744B |
| November 11, 2026 | 1.744B |
| November 10, 2026 | 1.756B |
| November 09, 2026 | 1.799B |
| November 06, 2026 | 1.777B |
| November 05, 2026 | 1.744B |
| November 04, 2026 | 1.864B |
| November 03, 2026 | 1.791B |
| November 02, 2026 | 1.734B |
| October 30, 2026 | 1.803B |
| October 29, 2026 | 1.878B |
| October 28, 2026 | 1.898B |
| October 27, 2026 | 1.883B |
| October 26, 2026 | 1.855B |
| October 23, 2026 | 1.831B |
| October 22, 2026 | 1.894B |
| October 21, 2026 | 1.836B |
| October 20, 2026 | 1.815B |
| October 19, 2026 | 1.781B |
| October 16, 2026 | 1.784B |
| October 15, 2026 | 1.814B |
| October 14, 2026 | 1.797B |
| October 13, 2026 | 1.764B |
| October 12, 2026 | 1.789B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.803B |
| October 08, 2026 | 1.745B |
| October 07, 2026 | 1.717B |
| October 06, 2026 | 1.674B |
| October 05, 2026 | 1.678B |
| October 02, 2026 | 1.693B |
| October 01, 2026 | 1.709B |
| September 30, 2026 | 1.742B |
| September 29, 2026 | 1.803B |
| September 28, 2026 | 1.817B |
| September 25, 2026 | 1.806B |
| September 24, 2026 | 1.827B |
| September 23, 2026 | 1.801B |
| September 22, 2026 | 1.837B |
| September 21, 2026 | 1.829B |
| September 18, 2026 | 1.867B |
| September 17, 2026 | 1.875B |
| September 16, 2026 | 1.875B |
| September 15, 2026 | 1.765B |
| September 14, 2026 | 1.802B |
| September 11, 2026 | 1.761B |
| September 10, 2026 | 1.762B |
| September 09, 2026 | 1.781B |
| September 08, 2026 | 1.757B |
| September 04, 2026 | 1.758B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| enGene Therapeutics, Inc. | -71.62M |
| Medicus Pharma Ltd. | 14.97M |
| Xenon Pharmaceuticals, Inc. | 3.033B |
| Psyence Biomedical Ltd. | -- |
| Agenus, Inc. | 487.93M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.70M |
| Revenue (Quarterly) | 83.70M |
| Total Expenses (Quarterly) | 52.00M |
| EPS Diluted (Quarterly) | 0.2345 |
| Gross Profit Margin (Quarterly) | 90.08% |
| Profit Margin (Quarterly) | 37.88% |
| Earnings Yield | 14.56% |
| Operating Earnings Yield | 6.73% |
| Normalized Earnings Yield | 14.56 |